Wave Life Sciences Starts Phase 2a Trial of WVE-007 with Tirzepatide for Obesity
WVE is trading near its 52-week low of $4.2 (7.1% above the low).
Summary
Wave Life Sciences has initiated a Phase 2a trial combining its GalNAc-siRNA WVE-007 with tirzepatide in obese adults with type 2 diabetes. The placebo-controlled study will test 240 mg and 400 mg doses of WVE-007 alongside weekly tirzepatide in patients with BMI 35-50. This marks a key step in the company's INLIGHT program, which also includes an ongoing monotherapy trial and a planned maintenance trial to prevent weight regain after stopping incretins, expected to start in H2 2026. Preclinical data showed the combination doubled weight loss versus GLP-1 alone, and WVE-007 may preserve muscle mass—a differentiator in the obesity space. With $490.6M in cash as of Q2 2026, the company is well-funded to advance this program. Investors will watch for early safety and efficacy signals from this combination trial, though data readouts are likely a year or more away.
At the time of this announcement, WVE was trading at $4.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $857.2M. The 52-week trading range was $4.20 to $21.73. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.